Gynecologic Oncology
Research activity includes advanced or recurrent endometrial cancer, with interest in immunotherapy and targeted treatment approaches used in first-line disease management.
- Endometrial cancer
- Durvalumab
- Olaparib
Clinical interest extends to pMMR disease and treatment settings involving platinum-based chemotherapy.
Breast Cancer
The sponsor funds studies in HR-positive, HER2-negative advanced breast cancer, with focus on endocrine-based treatment combinations and biomarker-linked disease.
- Fulvestrant
- Capivasertib
- PIK3CA, AKT1, PTEN
Work in this area reflects interest in molecularly altered breast cancer and later-line treatment sequencing.
Thoracic Oncology
Clinical research includes small cell lung cancer, particularly limited-stage disease after chemoradiotherapy, with attention to post-treatment disease control.
- Durvalumab
- Limited-stage small cell lung cancer
- Consolidation treatment
This area centers on immune-based therapy in patients without progression following definitive local treatment.
Haematologic Malignancies
The sponsor is also involved in studies of mantle cell lymphoma, with interest in combination treatment strategies for newly diagnosed disease.
- Acalabrutinib
- R-CHOP
- Previously untreated mantle cell lymphoma
Research activity in this field focuses on B-cell lymphoma treatment and targeted therapy alongside established chemotherapy regimens.
